Similar articles

• Modelling the cost effectiveness of TNF-alpha antagonists in the management of rheumatoid arthritis: results from the British Society for Rheumatology Biologics Registry.

  Brennan A, Bansback N, Nixon R, Madan J, Harrison M, Watson K, Symmons D. Brennan A, et al. Rheumatology (Oxford). 2007 Aug;46(8):1345-54. doi: 10.1093/rheumatology/kem115. Epub 2007 Jun 11. Rheumatology (Oxford). 2007. PMID: 17562686
• [Cost effectiveness of pharmaceutical innovations. Health economic aspects of rheumatoid arthritis treatment with TNF-alpha antagonists].

  Kulp W, Greiner W, Graf von der Schulenburg JM. Kulp W, et al. Pharm Unserer Zeit. 2003;32(5):420-5. doi: 10.1002/pauz.200300042. Pharm Unserer Zeit. 2003. PMID: 14526463 Review. German. No abstract available.
• Cost-effectiveness of abatacept in patients with moderately to severely active rheumatoid arthritis and inadequate response to tumor necrosis factor-alpha antagonists.

  Vera-Llonch M, Massarotti E, Wolfe F, Shadick N, Westhovens R, Sofrygin O, Maclean R, Li T, Oster G. Vera-Llonch M, et al. J Rheumatol. 2008 Sep;35(9):1745-53. Epub 2008 Jul 15. J Rheumatol. 2008. PMID: 18634164
• PHARMAC responds on TNF inhibitors for inflammatory arthritis.

  Metcalfe S, Moodie P, Grocott R, Wilkinson T. Metcalfe S, et al. N Z Med J. 2005 Dec 16;118(1227):U1799. N Z Med J. 2005. PMID: 16372039 No abstract available.
• Biologic therapy for early rheumatoid arthritis: the latest evidence.

  Castro-Rueda H, Kavanaugh A. Castro-Rueda H, et al. Curr Opin Rheumatol. 2008 May;20(3):314-9. doi: 10.1097/BOR.0b013e3282f5fcf6. Curr Opin Rheumatol. 2008. PMID: 18388524 Review.